Matt Hoffman, Associate Editorial Director for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He executive produces the NeurologyLive Mind Moments® podcast, and hosted the Medical World News show Deep Dive. Follow him on Twitter @byMattHoffman or email him at mhoffman@neurologylive.com
FT218 Receives Tentative Approval for EDS, Cataplexy in Adults With Narcolepsy
July 20th 2022Expected to be marketed as Lumryz by Avadel Pharmaceuticals, the extended-release oral suspension sodium oxybate’s final approval is pending the disposition of the REMS patent listed in the FDA’s Orange Book.
Learning From Patients and Looking to the Future of Movement Disorder Care
July 19th 2022Jill Farmer, DO, MPH, director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute, spoke at length about the recent ATMRD Congress, the state of care for movement disorders, and her hopes for the horizon of therapy and treatment.
Apomorphine Sublingual Film Treatment for Parkinson Disease May Not Require Use of Antiemetics
June 20th 2022After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.
The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies
June 19th 2022In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.
Physician Estimates of Needle Phobia Might Be Overstated Among Patients With Parkinson Disease
June 18th 2022A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.